Dr. Helen Torley, President and CEO of Halozyme, stated that the company’s analysis of the Centers for Medicare & Medicaid Services (CMS) proposal, alongside the statutory framework of the One Big Beautiful Bill Act, suggests no threat to its financial trajectory. Beyond royalty stability, the firm expects no disruption to its ability to secure new partnership agreements for its ENHANZE drug delivery technology.
The company’s outlook relies on specific provisions within the CMS draft that preserve protections for orphan drugs and account for the market entry of biosimilars. Halozyme intends to maintain a dialogue with federal regulators to advocate for policies that prioritize therapeutic innovation. The biopharmaceutical firm continues to license its proprietary enzyme technology to major global partners, including Roche, Takeda, and Pfizer, to facilitate subcutaneous drug delivery.
Comments (0)
No comments yet. Be the first!